INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMERPRNewsWire • Thursday
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program EndsBenzinga • 10/16/26
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMABusiness Wire • 10/16/26
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026Business Wire • 08/10/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMERGlobeNewsWire • 07/21/26
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?The Motley Fool • 07/08/26
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law FirmGlobeNewsWire • 07/08/26
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory DivideBenzinga • 06/26/26
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMABusiness Wire • 06/26/26
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool • 06/22/26
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?The Motley Fool • 06/20/26
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' NowZacks Investment Research • 06/04/26